12/31/2025
Nothing here should be surprising. A major new Lancet meta-analysis just confirmed what many clinicians are seeing in real-world practice.
When GLP-1 medications are discontinued, most people regain weight and experience measurable deterioration in metabolic health.
Across eighteen randomized controlled trials, stopping GLP-1 therapy led to significant weight regain along with worsening HbA1c, fasting glucose, blood pressure, BMI, and waist circumference.
This is not just cosmetic weight regain.
The authors describe this pattern as metabolic rebound.
GLP-1 drugs suppress appetite and alter satiety signaling while they are present. What they do not do is resolve the underlying drivers of obesity in the first place reestablish durable appetite regulation systems.
So when the medication is removed, hunger returns, metabolic rate is lower, insulin sensitivity is worse, and visceral fat tends to return.
This paper shows that GLP-1 use without parallel lifestyle and muscle rebuilding does not create lasting metabolic change. It creates reliance on continued pharmacologic control.
Long-term success requires rebuilding metabolic capacity alongside any medication use.
Without that, rebound is predictable.
We have always been a huge advocate for lifestyle change, Its at our very core, and when we introduced our GLP support at the start of 2025 it was directly to ensure people using these medications had the right guidance - making their progress healthy and sustainable.
